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Case series

Type II endometrial cancers with minimal, non-invasive residual disease on
ﬁnal pathology: What should we do next?
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There are minimal data regarding the management of high risk endometrial cancer histologies lacking invasive
disease on the ﬁnal pathology specimen. This study examines a cohort of these patients and assesses outcomes
including time to recurrence and risk of death after management with and without adjuvant therapies.
Endometrial cancer patients with minimal or no remaining invasive disease on ﬁnal pathologic specimen
from 1995 to 2010 were included. Surgical procedure was at the discretion of the operating physician. Electronic
medical records were used to abstract relevant clinicopathologic data and standard statistical methods were
employed.
70 patients met inclusion criteria, of which 26 were high grade histologies. Adjuvant therapies were given in
12 of 26 patients. 6/26 patients recurred, of which 50% were salvaged with therapy at time of recurrence.
Overall deaths occurred in 3 of 26 patients in the high risk cohort.
Less than half of the high risk cohort received adjuvant therapies after surgical management. No histologic
type was found to increase risk of recurrence, and treatment with initial adjuvant therapy did not signiﬁcantly
reduce recurrence risk. Large scale prospective trials are needed to aid in management of this unique endometrial cancer population.

1. Introduction
Endometrial cancer continues as the most commonly diagnosed
gynecologic malignancy with 63,000 new cases in 2018 (Cancer Facts,
and Figures Atlanta, Georgia, 2018). Endometrial cancer is separated
into type 1 carcinomas that includes grade 1 and 2 endometrioid
histologies that are less aggressive and often associated with excess
circulating estrogen, and type 2, high risk carcinomas, which include all
other types (serous, clear cell, carcinosarcoma, mixed, undiﬀerentiated
and grade 3 endometrioid histology) and portend a poorer prognosis. In
addition, type 2 carcinomas tend to present at advanced stages with
extrauterine spread at time of diagnosis (Goﬀ et al., 1994). The NCCN
recommendations for stage IA high risk carcinomas include observation
or chemotherapy, with or without vaginal brachytherapy (VBT) or external beam radiation, with or without brachytherapy (National
Comprehensive Cancer Network, 2018), demonstrating the wide range

of adjuvant therapies endorsed by experts. A clinical dilemma then
arises when an aggressive histology is found on work-up, but on ﬁnal
pathology there is minimal to no residual disease.
The majority of studies do not speciﬁcally focus on stage IA patients
in this clinical scenario, which would be useful for guiding adjuvant
therapies and counseling patients. We therefore aimed to review our
institutional experience managing high risk histologies with minimal
residual tumor, as well as report the clinical scenarios of patients who
recurred. We hypothesized that in those with high risk histologies,
treatment with adjuvant therapy after surgery would decrease recurrence risk.

⁎
Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 South
Euclid Avenue, Mail Stop 8064-34-905, St. Louis, MO 63110, United States of America.
E-mail address: kamills@wustl.edu (K.A. Mills).

https://doi.org/10.1016/j.gore.2019.05.007
Received 7 March 2019; Received in revised form 13 May 2019; Accepted 16 May 2019
Available online 23 May 2019
2352-5789/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Downloaded for Anonymous User (n/a) at Washington University School of Medicine from ClinicalKey.com by Elsevier on June 21, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.

Gynecologic Oncology Reports 29 (2019) 20–24

K.A. Mills, et al.

2. Methods

Table 1
Demographics.

2.1. Patient population
Women age 18–90 undergoing deﬁnitive surgical evaluation for
suspected early stage uterine cancers at Washington University in St.
Louis after endometrial biopsy or dilation and curettage from 1995 to
2010 were eligible for this IRB approved retrospective cohort study.
Patients were included if they had no evidence of residual disease,
disease conﬁned to a polyp, or non-invasive disease (endometrial involvement only) on ﬁnal hysterectomy specimen. High risk, high grade
histologies were deﬁned as uterine serous (USC), clear cell (CCC), grade
3 endometrioid (HGE), mixed (M), and carcinosarcoma (CS). Surgical
approach was performed at the discretion of the surgeon and during
this period, full lymph node dissections were performed. Data were
abstracted from electronic medical records, and baseline characteristics
and demographic data as well as subsequent treatment, pathology, and
clinical outcomes were assessed. Patients without adequate staging, had
invasive disease, or did not have available follow up data were excluded. Vital status and duration of follow up was recorded for each
patient.

Age at diagnosis
Race
Black
Caucasian
Other
Ethnicity
Hispanic
Comorbidities
Hypertension
Diabetes
BMI at Time of Surgery
Histology
Endometrioid
Clear cell
Papillary serous
Carcinosarcoma
Mixed
Surgical Pathology
No residual malignancy
Malignancy limited to polyp
Malignancy limited to
endometrium
Initial treatment
Surgery only
Surgery and chemotherapy
Surgery, chemotherapy, and
radiation
ASA Score
2
3
4
Vital statusa
NED
DOD
LTFU
Recurrence
Years from diagnosis to last
contact

2.2. Adjuvant therapies
Initial therapies included observation, chemotherapy or radiation.
Patients who went on to recur were identiﬁed and location of recurrence and type of treatment oﬀered was abstracted.
2.3. Statistical analysis
All analyses were performed using SAS Software (v.9.4.; SAS
Institute, Cary, NC) and statistical signiﬁcance was deﬁned as p < .05.
Demographic and clinical data were compared among groups using
Fisher's exact tests for categorical data and Wilcoxon rank sum tests for
non-normal data distribution. Median disease recurrence durations
were compared using Wilcoxon rank sum and Kruskal-Wallis tests.
Kaplan-Meier curves were produced to visually demonstrate duration to
disease recurrence by histology type and treatment type.
3. Results

Grade 1 & 2

Grade 3

P

(n = 44)

(n = 26)

59.5
(54.4–68.3)

64.3
(58.5–72.9)

6 (13.6)
38 (86.4)
0 (0.0)

2 (7.7)
23 (88.5)
1 (3.9)

0 (0.0)

1 (3.9)

17 (38.6)
7 (15.9)
34.0
(30.0–42.5)

12 (46.2)
9 (34.6)
31.0
(28.0–38.0)

0.54
0.07
0.26

44 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

6
5
9
1
5

< 0.01
< 0.01
< 0.01
0.37
< 0.01
< 0.01

11 (25.0)
2 (4.6)
31 (70.5)

0 (0.0)
8 (30.8)
18 (69.2)

44 (100.0)
0 (0.0)
0 (0.0)

14 (53.8)
9 (34.6)
3 (11.5)

9 (20.5)
34 (77.3)
1 (2.3)

7 (26.9)
19 (73.1)
0 (0.0)

36 (81.8)
0 (0.0)
8 (18.2)
0 (0.0)
2.2 (0.1–5.9)

16 (61.5)
3 (11.5)
7 (26.9)
6 (23.1)
5.5 (3.7–7.6)

0.04
0.41

0.37

(23.1)
(19.2)
(34.6)
(3.8)
(19.2)

< 0.01

0.73

0.14

< 0.01
< 0.01

a

NED = No evidence of disease, DOD = dead of disease, LTFU = Lost to
follow up.

3.1. Demographics
64.0 years, p = .16). 10 out of the 12 (83.3%) of the adjuvantly-treated
patients had either mixed serous or pure serous histologies. The patient
with carcinosarcoma was recommended to receive adjuvant therapy
but did not receive it. The mean number of chemotherapy cycles given
was 4 ± 1.8, and in all cases a platinum and taxane regimen was given.
All patients who received radiation underwent high dose rate VBT to
the upper 3–4 cm of the vagina to a total of 21–36 Gy.

A total of 26 patients with high grade, high risk histology were
identiﬁed out of 70 patients without residual disease, disease conﬁned
to a polyp, or endometrium conﬁned disease within the study period
(Table 1). Overall the high risk cohort was comprised of grade 3 endometrioid (23.1%, n = 6), clear cell (19.2%, n = 5), serous (34.6%,
n = 9), mixed (19.2%, n = 5), and carcinosarcoma (3.8%, n = 1), respectively. Compared to low grade patients, high risk patients were
signiﬁcantly older (64.3 vs 59.9 years, p = .04), had been followed
longer (5.5 vs 2.2 years, p < .01), and had a higher risk of recurrence
(6 vs 0, p ≤.01), but otherwise had similar ASA scores, race distribution, and co-morbidities including hypertension, diabetes, and BMI. All
patients within the high risk cohort had residual disease on ﬁnal specimen, versus 33 (75%) of the low grade IA patients. No low grade
patients received adjuvant therapies.

3.3. Outcomes
Of the high risk cohort, 6 patients recurred (23.1%) with a median
follow up time of 5.5 years, and 50% of those recurrences were distant
recurrences that were not salvageable (Table 2). 3 out of 6 recurrences
were CCC and all 3 were treated with radiation with or without surgery
and all were alive without evidence of disease at recent follow up. The
other 3 were either pure serous or mixed serous, all of whom are now
dead from disease.
There was no increased risk of recurrence based on malignancy
limited to a polyp versus limited to the endometrium, histology, or
treatment with initial adjuvant therapy (Table 3). BMI was signiﬁcantly
higher in those who recurred (43.0 vs 30.5, p = .01), and hypertension
(100% vs 30%, p < .01) and diabetes (83% vs 20%, p < .01) were
more frequent, as well. 7 of the 26 patients (23.1%) were lost to follow

3.2. Initial treatment
14 of the high risk cohort received no further therapy, while 12 total
patients received adjuvant therapies. 9 patients received adjuvant
chemotherapy in addition to surgery (34.6%) and 3 received chemotherapy along with radiation (11.5%). No patients were treated with
radiation alone. There was no signiﬁcant diﬀerence in the average age
of those observed versus those receiving adjuvant therapy (68.8 vs.
21
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Table 2
Details of Recurrences.
Histology

Initial Therapy

Recurrence Location

Treatment for Recurrence

Outcome at last follow upa

Clear Cell
Clear Cell
Clear Cell
Serous
Serous
Mixed endometrioid and serous

None
None
None
6 cycles of platinum and taxane
3 cycles of platinum and taxane
1 cycle of platinum and taxane, refused additional
cycles

Vaginal cuﬀ
Vaginal cuﬀ
Vaginal cuﬀ
Distant
Distant
Distant and vaginal cuﬀ

Surgical resection plus radiation
Radiation
Surgical resection plus radiation
Surgery plus chemotherapy
Chemotherapy
Declined oﬀered chemotherapy

NED
NED
NED
DOD
DOD
DOD

a

NED = No evidence of disease, DOD = Dead of disease.

Table 3
Characteristics of Grade 3 patients by recurrence status.

Age at diagnosis
Race
Black
Caucasian
Other
Ethnicity
Hispanic
Comorbidities
Hypertension
Diabetes
Histology
Endometrioid
Clear cell
Serous
Carcinosarcoma
Mixed
Surgical Pathology
No residual malignancy
Malignancy limited to polyp
Malignancy limited to
endometrium
Initial treatment
Surgery only
Surgery and chemotherapy
Surgery, chemotherapy, and
radiation
BMI at time of surgery, Median
ASA Score
2
3
4
Vital statusa
NED
DOD
LTFU
Years from diagnosis to last
contact, Median (IQR)

Recurred
(n = 6)

No recurrence
(n = 20)

P

69.5
(63.3–72.0)

64.0 (57.9–73.3)

0.62

0 (0.0)
6 (100.0)
0 (0.0)

2 (10.0)
17 (85.0)
1 (5.0)

0 (0.0)

1 (5.0)

6 (100.0)
5 (83.3)

6 (30.0)
4 (20.0)

< 0.01
< 0.01

0
3
2
0
1

6
2
7
1
4

0.28
0.06
> 0.99
> 0.99
< 0.99
0.33

> 0.99

> 0.99

(0.0)
(50.0)
(33.3)
(0.0)
(16.7)

(30.0)
(10.0)
(35.0)
(5.0)
(20.0)

0 (0.0)
3 (50.0)
3 (50.0)

0 (0.0)
5 (25.0)
15 (75.0)

3 (50.0)
2 (33.3)
1 (16.7)

11 (55.0)
7 (35.0)
2 (10.0)

43.0
(32.0–47.0)

30.5 (27.5–35.5)

1 (16.7)
5 (83.3)
0 (0.0)

6 (30.0)
14 (70.0)
0 (0.0)

3 (50.0)
3 (50.0)
0 (0.0)
7.0 (3.7–9.0)

13 (65.0)
0 (0.0)
7 (35.0)
5.0 (2.0–7.6)

Fig. 1. Time to Recurrence Based on Histology.

4. Discussion
Prior studies have examined the outcomes of early stage patients
with various high risk histologies both with and without adjuvant
therapies. Huh et al. retrospectively evaluated a series of 60 patients at
four academic institutions with surgically staged IA-IC uterine serous
cancer treated with observation or combinations of chemotherapy and
radiation; there was no demonstrated improvement in overall survival
in those treated with adjuvant radiation compared to observation, with
no recurrences or disease related deaths in the small number of patients
treated with at least chemotherapy (n = 8) (Huh et al., 2003). Further
studies attempted to clarify outcomes in USC with minimal invasion.
Hui et al. evaluated USC patients, surgically staged, with invasion
limited to the endometrium or limited to a polyp, and in 22 patients
with disease limited to uterus no recurrence was noted during follow
up, although the use of adjuvant therapies is not reported (Hui et al.,
2004). Kelly et al. evaluated 74 USC patients stage IA-IC, of which 12
had no residual uterine disease on ﬁnal specimen; Platinum based
therapy was associated with a signiﬁcant improvement in both disease
free and overall survival (Kelly et al., 2005). Speciﬁcally, those with no
residual disease had no recurrences irrespective of adjuvant therapy
given. Our own experience found that the patients who recurred with
USC after no residual disease, even in the setting of adjuvant therapy,
did poorly and succumbed to disease; however out of the included 9
USC patients, only 3 recurred total. Interestingly, all mixed tumors
identiﬁed in our study included some component of serous tumor in the
prior to surgery specimen. It has been suggested that tumor behavior is
often driven by serous histology even in a mixed setting, and in our
results 80% of mixed tumors received adjuvant therapy up front, with
only 1 recurrence.
Clear cell carcinoma is even rarer with large scale prospective trials
evaluating early stage management lacking. The Society of Gynecologic
Oncology clinical practice committee recommends consideration for

> 0.99

0.01
> 0.99

< 0.01

0.47

a
NED = No evidence of disease, DOD = dead of disease, LTFU = Lost to
follow up.

up, deﬁned as no follow up within the prior three years until study end,
and were all within the no recurrence group. Overall, 3 of the 26 total
patients (11.5%) were dead of disease at study end.
Kaplan Meier curves were used to compare time to recurrence
among the diﬀerent histological subtypes. Interestingly, while the CCC
patients recurred quickly (n = 3, average 14.9 months versus
80.1 months in the serous cohort, p = .08), as mentioned, 100% salvage
rate was achieved (Fig. 1); no grade 3 endometrioid histology patients
recurred during the study period. Given the small sample size, no
multivariable analysis could be performed.
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addition, while no deﬁnitive conclusions can be drawn about the patients who succumbed to recurrence, in all settings pure USC or mixed
USC was present on initial biopsy. Additionally, all of these patients
received initial adjuvant therapy (ranging from 1 to 6 cycles of carboplatin and taxane). Further studies, including meta-analyses and prospective data if possible, are essential to drawing ﬁrm conclusions about
management of these patients with high risk but minimal to no residual
disease on ﬁnal pathology.

adjuvant therapies in early stage disease (Olawaiye and Boruta, 2009).
A Taiwanese Gynecologic Oncology Group study sought to retrospectively investigate surgically staged CCC and included 80 stage I
patients, of which 37 were observed when tumors were < 2 cm and/or
stage IA and found an overall survival of 93% (Hsu et al., 2014). Another retrospective investigation of 99 CCC patients, including 16 stage
IA patients, found that in the 22 stage I and II patients with thoroughly
sampled lymph nodes (> 20 pelvic and paraaortic nodes) and varying
therapies including observation pursued, only 1 patient recurred
(Thomas et al., 2008). CCC is often studied concurrently with USC or in
a mixed setting, making conclusions diﬃcult to apply more broadly.
Velker et al. reported a single institution experience of CCC and USC
with < 50% myometrial invasion undergoing adjuvant therapy versus
observation, of which only 83% of the cohort had lymph node sampling. Of the 77 patients included, 12 total recurrences were documented and were not signiﬁcantly diﬀerent between groups. In a subgroup analysis of the observed patients, patients with myometrial
invasion had a non-signiﬁcant trend towards decreased recurrence free
survival (75% versus 93%) (Velker et al., 2016). In our cohort, patients
with pure clear cell histologies did well even with recurrence, and were
alive and without evidence of disease after appropriate therapies.
Carcinosarcoma (CS), remains an especially diﬃcult disease to
manage even at early stages, as greater than half of these patients will
have occult metastases (Yamada et al., 2000) and suﬀer high recurrence
rates with a propensity to recur outside the pelvis (Silverberg et al.,
1990). A multiinstitutional review of 303 stage I-III patients identiﬁed
70 observed stage I patients compared to 29 treated with chemotherapy, 26 radiation therapies, and 30 with combination chemotherapy and radiation. Compared to those stage I and II patients who
were treated with chemotherapy, those who were observed had an increased risk of death by greater than four times (Dickson et al., 2015),
though authors did not report separate data on stage I patients with
minimal or no invasive disease. In our cohort, only one carcinosarcoma
without residual disease was evaluable and has unfortunately been lost
to follow up for > 3 years. More evaluations of patients in this clinical
scenario should be considered critical areas of investigation.
High grade endometrioid histology has historically been included
within high intermediate risk studies GOG 99 and 249. GOG 99 aimed
to outline high intermediate patient subgroups and determine if the
addition of adjuvant external beam irradiation lowered the risk of recurrence (Keys et al., 2004), and GOG 249, of which ﬁnal publication is
pending, showed no improvement in outcomes of high risk patients
deﬁned by GOG 99 parameters who were then treated with VBT and
chemotherapy as compared to standard whole pelvic radiation (Pelvic
Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel,
and Carboplatin in Treating Patients With High-Risk Stage I or Stage II
Endometrial Cancer, 2018). Neither of these trials delineate if preoperative ﬁndings of a grade 3 tumor without evidence of residual
disease warrants postoperative radiation therapy. In addition, the recently published PORTEC 3 trial did not demonstrate an improvement
in survival with the addition of chemotherapy to pelvic radiation even
those with invasive stage IA, grade 3 disease (de Boer et al., 2018). In
our cohort, no pure grade 3, endometrioid histology tumors recurred.
There are a number of limitations to our study. Given its retrospective nature, it is subject to biases including confounders, chart review errors, and in this case, a > 20% loss to follow up rate. In addition, the overall sample size was small and we were unable to create a
mutivariable model for risk of recurrence or overall survival.
In our study, less than half of the high risk histology patients received adjuvant therapies and treatment with therapy was not conclusively linked to recurrence risk. Concordant with published data
(Calle et al., 2003), obesity and metabolic dysfunction were also more
common in the recurrence group. Our experience suggests that in patients with high risk histologies, clear cell carcinomas, while recurring
quickly after observation in three patients, were 100% curable with
salvage therapy, which suggests upfront observation is reasonable. In
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